JP2020534017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534017A5 JP2020534017A5 JP2020516818A JP2020516818A JP2020534017A5 JP 2020534017 A5 JP2020534017 A5 JP 2020534017A5 JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020534017 A5 JP2020534017 A5 JP 2020534017A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- composition
- antigen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 12
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- -1 TCR gamma / delta Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023103361A JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2024215117A JP2025061650A (ja) | 2017-09-23 | 2024-12-10 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562373P | 2017-09-23 | 2017-09-23 | |
| US201762562374P | 2017-09-23 | 2017-09-23 | |
| US62/562,373 | 2017-09-23 | ||
| US62/562,374 | 2017-09-23 | ||
| PCT/US2018/052253 WO2019060750A2 (en) | 2017-09-23 | 2018-09-21 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103361A Division JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534017A JP2020534017A (ja) | 2020-11-26 |
| JP2020534017A5 true JP2020534017A5 (enExample) | 2021-10-28 |
| JP7303802B2 JP7303802B2 (ja) | 2023-07-05 |
Family
ID=65810903
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516818A Active JP7303802B2 (ja) | 2017-09-23 | 2018-09-21 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2023103361A Pending JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2024215117A Pending JP2025061650A (ja) | 2017-09-23 | 2024-12-10 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103361A Pending JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2024215117A Pending JP2025061650A (ja) | 2017-09-23 | 2024-12-10 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11555072B2 (enExample) |
| EP (1) | EP3684369A4 (enExample) |
| JP (3) | JP7303802B2 (enExample) |
| KR (1) | KR102783937B1 (enExample) |
| CN (1) | CN111372590A (enExample) |
| AU (2) | AU2018338322B2 (enExample) |
| CA (1) | CA3076611A1 (enExample) |
| IL (1) | IL273484B2 (enExample) |
| WO (1) | WO2019060750A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271462A1 (en) | 2013-03-13 | 2014-09-18 | Imaginab, Inc. | Antigen binding constructs to cd8 |
| CN115960230A (zh) | 2015-08-07 | 2023-04-14 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| US11122038B1 (en) * | 2017-05-18 | 2021-09-14 | United Services Automobile Association (Usaa) | Methods and systems for authentication of new users |
| EP3898677A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| SG11202106347PA (en) | 2018-12-21 | 2021-07-29 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| EP3898676A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| CN113573782B (zh) | 2018-12-21 | 2025-12-16 | Ose免疫疗法公司 | 针对人pd-1的双功能分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US20220177579A1 (en) * | 2019-04-08 | 2022-06-09 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| EP4244242A1 (en) | 2020-11-16 | 2023-09-20 | Technische Universität München | Bioorthogonal reporter gene system |
| AU2021381768A1 (en) * | 2020-11-18 | 2023-06-22 | Memorial Sloan Kettering Cancer Center | Anti-gpa33 multi-specific antibodies and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307026B1 (en) * | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| DE69331735T2 (de) * | 1992-12-10 | 2002-09-26 | Celltech Therapeutics Ltd., Slough | Gegen das A33 Antigen gerichtete Humanisierte Antikörper |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP2002512776A (ja) * | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
| WO2006028197A1 (ja) * | 2004-09-06 | 2006-03-16 | Kirin Beer Kabushiki Kaisha | 抗a33抗体 |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| CN106794238A (zh) | 2014-09-30 | 2017-05-31 | 威斯康星州医药大学股份有限公司 | 用于靶向治疗以治疗神经疾病的通用平台 |
| JP6970017B2 (ja) | 2015-02-09 | 2021-11-24 | メモリアル スローン ケタリング キャンサー センター | ヒトａ３３抗原とｄｏｔａ金属複合体に親和性を有する多重特異性抗体及びその使用 |
| DK3280432T3 (da) * | 2015-04-06 | 2021-04-26 | Subdomain Llc | Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf |
-
2018
- 2018-09-21 JP JP2020516818A patent/JP7303802B2/ja active Active
- 2018-09-21 WO PCT/US2018/052253 patent/WO2019060750A2/en not_active Ceased
- 2018-09-21 EP EP18859251.3A patent/EP3684369A4/en active Pending
- 2018-09-21 KR KR1020207011796A patent/KR102783937B1/ko active Active
- 2018-09-21 CA CA3076611A patent/CA3076611A1/en active Pending
- 2018-09-21 AU AU2018338322A patent/AU2018338322B2/en active Active
- 2018-09-21 CN CN201880075541.7A patent/CN111372590A/zh active Pending
- 2018-09-21 US US16/649,617 patent/US11555072B2/en active Active
-
2020
- 2020-03-22 IL IL273484A patent/IL273484B2/en unknown
-
2023
- 2023-06-23 JP JP2023103361A patent/JP2023138957A/ja active Pending
- 2023-11-03 US US18/501,782 patent/US20240327511A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215117A patent/JP2025061650A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204844A patent/AU2025204844A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534017A5 (enExample) | ||
| ES3003809T3 (en) | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides | |
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| CN108124445B (zh) | Ctla4抗体、其药物组合物及其用途 | |
| KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
| CN110214152B (zh) | 模块化四聚体双特异性抗体平台 | |
| JP7450585B2 (ja) | ＣＤ６６ｃに特異的に結合する抗体およびその用途 | |
| JP2020523029A5 (enExample) | ||
| KR102380150B1 (ko) | Gitr 항체, 방법, 및 용도 | |
| WO2022161425A1 (zh) | 抗tnfr2人源化抗体及其用途 | |
| JP2021521245A (ja) | キレート化された放射性核種に対する抗体および除去剤 | |
| CN117304325A (zh) | B7h3抗体及其用途 | |
| EP3703736A1 (en) | Bispecific antibodies and methods of making and using thereof | |
| EP4238990A1 (en) | Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof | |
| CN118339187A (zh) | 抗pd-1抗体及其用途 | |
| JP2022531229A (ja) | 併用治療 | |
| WO2025067496A1 (zh) | 靶向baff-r的全人源抗体、car-t细胞及其应用 | |
| JPWO2021046331A5 (enExample) | ||
| JPWO2020210232A5 (enExample) | ||
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| JPWO2020264211A5 (enExample) | ||
| CA3107524C (en) | Humanized Monocolonial Antibody Against CTLA4: Preparation Method and Application | |
| KR20240127523A (ko) | 항-cntn4 항체 및 그의 용도 | |
| JPWO2022032004A5 (enExample) |